1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
HLB Therapeutics Co., Ltd.

HLB Therapeutics Co., Ltd.

KKRX:115450
2,735.00
KRW
+65.00
(+2.43%)
-108.55EPS
256.97BMarket Cap
HLB Therapeutics Co., Ltd.
KRX:115450
(Korea Stock Exchange)

Recent

price

2,735.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
916.24
1,099.46
2,225.21
780.9
422.09
371.66
357.57
325.7
790.57
1,051.87
713.98
676
598.95
665.63
590.21
753.91
766.42
Revenue per Share
337.73
-2,310.43
-233.94
-147.33
-38.53
-95.26
-104.99
-91.45
82.98
-292.97
-281.11
-266.72
-160.37
-29.14
-244.9
-100
-103.12
Basic EPS, GAAP
200.72
102.61
-469.76
-79.79
-143.9
-293.59
-273.08
-374.23
-95.55
-290.28
-327.98
-235.76
-203.35
-30.79
-80.02
-197.73
-169.86
Free Cash Flow per Basic Share
- -
- -
5.15
1.83
1.37
1.2
2.49
1.48
0.44
0.83
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,175.09
706.81
492.99
362.54
516.34
649.66
672.25
712.97
1,202.1
1,095.81
1,419.96
1,619.44
1,614.49
1,974.62
1,790.84
1,704.42
1,715.74
Book Value per Share
2,167.43
145.23
31.21
13.91
502.48
376.96
176.76
25.48
370.51
128.82
479.78
774.87
662.64
997.77
777.85
598.28
545.28
Tangible Book Value per Share
12
14
27
27
42
45
50
53
55
56
60
64
71
79
93
92
88
Basic Weighted Avg Shares
11,318
15,782
59,301
20,859
17,618
16,782
17,710
17,152
43,585
58,966
42,930
43,586
42,403
52,591
54,932
69,561
67,561
Sales/Revenue/Turnover
29.48
4.22
-1.53
-8.68
-4.97
-18.73
-25.32
-26.18
-7.24
-14.99
-26.24
-25.48
-17.7
-16.59
-13.88
-5.08
-7.68
Operating Margin (%)
317
361
983
702
635
502
476
464
472
688
701
1,701
1,666
8,479
8,092
4,622
3,429
Depreciation Expense
4,172
-33,164
-6,235
-3,935
-1,608
-4,301
-5,200
-4,816
4,575
-16,423
-16,902
-17,197
-11,354
-2,302
-22,793
-9,227
-9,090
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
36.86
-210.14
-10.51
-18.87
-9.13
-25.63
-29.36
-28.08
10.5
-27.85
-39.37
-39.46
-26.78
-4.38
-41.49
-13.26
-13.45
Profit Margin (%)
14,012
-11,754
-7,163
-13,681
13,200
11,867
-3,742
-4,244
15,158
1,920
19,524
56,536
21,384
23,034
22,221
48,286
11,883
Working Capital
1,167
932
2,932
1,372
3,907
10,690
- -
- -
- -
190
219
321
185
1,962
5,371
28,337
18,566
LT Debt
27,634
18,379
14,087
10,379
22,516
33,486
36,962
44,012
81,432
76,096
100,306
130,039
128,116
171,519
181,868
173,863
176,018
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
19.8
-143.22
-38.29
-32.91
-9.92
-16.43
-16.26
-13.32
8.54
-24.77
-22.05
-16.53
-9.65
-1.66
-14.34
-6
-5.96
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10,923
12,213
21,758
LT Borrowings
9,444
25,359
15,936
LT Finance Leases
1,790
2,978
2,630
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
88
Market Capitalization
253,132
251,873
256,971

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
53,657
74,500
46,420
Cash, Cash Equivalents & STI
26,701
45,998
19,331
Accounts Receivable, Net
15,519
14,306
12,817
Inventories
6,696
7,237
7,027
Total Current Liabilities
46,198
26,214
34,537
Payables & Accruals
- -
- -
- -
ST Debt
10,923
12,213
21,758
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.34%
12.73%
-4.4%
Free Cash Flow
44.44%
47.96%
144.95%
Net Income, GAAP
8.1%
143.72%
-59.52%
Sales/Revenue/Turnover
21.85%
10.78%
26.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,755
11,662
14,052
16,463
54,932
2025
15,047
15,672
16,064
22,778
69,561
2026
13,046
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.78
-246.71
-28.12
21.36
-244.9
2025
-48.57
0.76
-62.16
7.29
-100
2026
-49
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
HLB Therapeutics Co., Ltd. operates as a biopharmaceutical company specializing in the development of innovative new drugs primarily focused on rare diseases and severe ophthalmic and neurological disorders. Its core products and pipeline include gene medicines and cell medicines, with key developments such as GBT-201 utilizing Thymosin beta for ophthalmic diseases like dry eye syndrome and neurotrophic keratopathy, and OKN-007 targeting glioblastoma brain tumors. The company also engages in cold chain logistics supporting biologics distribution, quasi-drugs including alcohol swabs, and bio-healthcare products leveraging advanced nanomaterials. Operational in South Korea and internationally, HLB Therapeutics targets patient populations with hard-to-treat conditions and pursues first-in-class and best-in-class therapies. Founded in 2003 and headquartered in South Korea, HLB Therapeutics has undergone significant strategic transformations recently. In late 2024, the company announced the spin-off of its electronics business to concentrate exclusively on its core biopharmaceutical and cold chain businesses. This move is intended to strengthen focus on accelerating drug development in neurotrophic keratitis and brain tumor treatments while expanding its cold chain business expected to grow 35% annually through 2026. Additionally, HLB Therapeutics secured KRW17 billion in funding from strategic investors, including Synergy Asset Management, to fuel its drug development pipeline and global licensing efforts. The company has also reinforced collaborations for biomedical technology advancements and is actively pursuing FDA approvals and global partnerships to enhance its competitive position in biotechnology and rare disease therapeutics. HLB Therapeutics operates its business through specialized divisional work combining drug development, licensing-in clinical-stage candidates with verified safety and efficacy, clinic and license-out strategies to global pharmaceutical firms, and early-stage funding initiatives. It maintains a diverse product portfolio ranging from gene and cell therapy candidates to medical devices and femtech supplies, supported by advanced research in peptides and bio-materials through subsidiaries. The company leverages global clinical trials and strategic alliances, aiming to maximize investor returns and corporate value by focusing on innovative drug development and sustainable growth in the biotechnology sector. This description reflects HLB Therapeutics' comprehensive pharmaceutical product offerings, strategic realignments in the last 1-2 years, and ongoing expansion into global markets through licensing and partnerships.